RT Journal Article
SR Electronic
T1 Effectiveness of the Single-Dose Ad26.COV2.S COVID Vaccine
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.09.10.21263385
DO 10.1101/2021.09.10.21263385
A1 Jennifer M. Polinski
A1 Andrew R. Weckstein
A1 Michael Batech
A1 Carly Kabelac
A1 Tripthi Kamath
A1 Raymond Harvey
A1 Sid Jain
A1 Jeremy A. Rassen
A1 Najat Khan
A1 Sebastian Schneeweiss
YR 2021
UL http://medrxiv.org/content/early/2021/09/12/2021.09.10.21263385.abstract
AB Background Randomized trials demonstrated efficacy of Ad26.COV2.S, a single-dose COVID-19 vaccine. Data assessing effectiveness in clinical practice and its stability over time since vaccination and against Delta variants are needed.Methods Using U.S. insurance claims data through July 2021, we identified individuals newly vaccinated with Ad26.COV2.S and up to 10 unvaccinated individuals matched exactly by age, sex, date, location, comorbidity index plus 17 COVID-19 risk factors via propensity score (PS) matching. We estimated Vaccine Effectiveness (VE) with 95% confidence intervals (CI) for observed COVID-19 and COVID-19-related hospitalization, nationwide and stratified by age, immunocompromised status, calendar time, and states with high incidence of the Delta variant. We corrected VE estimates for under-recording of vaccinations in insurance data.Results Among 390,517 vaccinated and 1,524,153 matched unvaccinated individuals, VE was 79% (95% CI, 77% to 80%) for COVID-19 and 81% (79% to 84%) for COVID-19-related hospitalizations. VE was stable over calendar time. Among states with high Delta variant incidence, VE during June/July 2021 was 78% (73% to 82%) for infections and 85% (73% to 91%) for hospitalizations. VE for COVID-19 was higher in individuals <50 years (83%; 81% to 85%) and lower in immunocompromised patients (64%; 57% to 70%). All estimates were corrected for under-recording; uncorrected VE was 69% (67% to 71%) and 73% (69% to 76%), for COVID-19 and COVID-19-related hospitalization, respectively.Conclusions These non-randomized data across U.S. clinical practices show high and stable vaccine effectiveness of Ad26.COV2.S over time before the Delta variant emerged to when the Delta variant was dominant.Competing Interest StatementDr. Polinski, Mr. Weckstein, Dr. Batech, Ms. Kabelac and Dr. Rassen are employees of and own stock options or equity in Aetion, a software-enabled healthcare analytics company. Dr. Kamath, Mr. Harvey, Mr. Jain and Dr. Khan are employees of Janssen R&D, the manufacturer of the studied vaccine Ad26.COV2.S. Dr. Schneeweiss (ORCID# 0000-0003-2575-467X) is participating in investigator-initiated grants to the Brigham and Women's Hospital from Boehringer Ingelheim unrelated to the topic of this study. He is a consultant to Aetion Inc. of which he owns equity. His interests were declared, reviewed, and approved by the Brigham and Women's Hospital in accordance with their institutional compliance policies.Funding StatementThis work was funded by Janssen R&DAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study was approved by the New England institutional review board.All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesData belong to third parties and cannot be shared publicly, however, upon reasonable request, researchers may get access to the data and analytics infrastructure for pre-specified collaborative analyses.